BioNTech SEBNTX +1.36%62 PB Ratio is 1.07 as of Jun. 27, 2026, which is 33% below its 10-year median of 1.59. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $89.10 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, BioNTech SE ranks better than 80.76% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), BioNTech SE's share price is $91.22. BioNTech SE's Book Value per Share for the quarter that ended in Mar. 2026 was $85.48. Hence, BioNTech SE's PB Ratio of today is 1.07.
The historical rank and industry rank for BioNTech SE's PB Ratio or its related term are showing as below:
BNTX'
s PB Ratio Range Over the Past 10 Years
Min: 0.88 Med: 1.59 Max: 29.27
Current: 1.07
During the past 10 years, BioNTech SE's highest PB Ratio was 29.27. The lowest was 0.88. And the median was 1.59.
BNTX's PB Ratio is ranked better than 80.76% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs BNTX: 1.07
During the past 12 months, BioNTech SE's average Book Value Per Share Growth Rate was 0.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 49.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of BioNTech SE was 247.60% per year. The lowest was 0.80% per year. And the median was 148.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioNTech SE PB Ratio Related Terms
BioNTech SE PB Ratio Historical Data
* Premium members only.
The historical data trend for BioNTech SE's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioNTech SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioNTech SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
BioNTech SE's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioNTech SE (BNTX) has a PB Ratio of 1.07 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioNTech SE and its competitors. This is 33% below median its historical median of 1.59. Over the past decade, BioNTech SE's PB Ratio has ranged from 0.88 to 29.27. According to the industry distribution chart, BioNTech SE ranks #237 out of 1232 companies in the Biotechnology industry, placing it in the top 19.2%.
Is BioNTech SE's PB Ratio too high?
BioNTech SE's current PB Ratio of 1.07 is 33% below median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 29.27. The Biotechnology industry median PB Ratio is 2.80. BioNTech SE's value of 1.07 is 61.8% below this industry median. Based on the distribution chart, BioNTech SE ranks #237 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's PB Ratio compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #237 out of 1232 companies for PB Ratio. This places BioNTech SE in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. BioNTech SE's value of 1.07 is 61.8% below this benchmark. Historically, BioNTech SE's own PB Ratio has ranged from 0.88 to 29.27 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 2.80, BioNTech SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current PB Ratio of 1.07 is 61.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current PB Ratio is 1.07, which is 33% below median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $89.10, compared to a current price of $91.22 — trading 2.4% above its estimated fair value. The current PB Ratio is 1.07, which is 33% below median its 10-year median of 1.59 and 61.8% below the Biotechnology industry median of 2.80. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioNTech SE (BNTX), the current PB Ratio is 1.07 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $91.22 is trading 2.4% above its estimated GF Value™ of $89.10.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
PB Ratio: 1.07 (33% below median its 10-year median of 1.59)
GF Value™: $89.10 vs. price of $91.22 (2.4% above fair value)
Industry Position: 61.8% below the Biotechnology median (#237 of 1232)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
